1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April.

Slides:

Advertisements

Similar presentations

1 Goals of a Lotronex ® Risk Management Program Toni Piazza-Hepp, Pharm.D. Deputy Director Division of Surveillance, Research and Communication Support.

Advertisements

5th Annual PBM Pharmacy Informatics Conference

Presentation based on Turner, J.R., New Drug Development, and Turner, J.R., Drug Cardiac Safety. Copyright © 2007, 2008 respectively, John Wiley & Sons,

Anne Burns, RPh Group Director, Practice Development and Research

ONDQA Perspective on Post Approval Changes Eric P. Duffy, PhD Director, Division of Post-Market Evaluation, ONDQA, CDER, FDA Public Meeting: Supplements.

1 Lotronex ® (alosetron HCl) Tablets Risk-Benefit Issues Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products.

The Food and Drug Administration Amendments Act of 2007: Implications of the Drug Safety Provisions Carolyn D. Jones, J.D., MPh Director, Regulatory Policy.

Food Advisory Committee Meeting December 16 and 17, 2014 Questions to the Committee Suzanne C. Fitzpatrick, PhD, DABT Senior Advisory for Toxicology Center.

Center for Drug Evaluation and Research August 2005 Electroretinography: The FDA’s Viewpoint Wiley A. Chambers, MD Deputy Director Division of Anti-Infective.

CASTRO VALLEY ADULT AND CAREER EDUCATION CMA PROGRAM FOOD AND DRUG ADMINISTRATION.

Regulatory Authority Governing Clinical Trials Anthony J. Minisi, MD Director, Cardiology Fellowship Program.

A S Nanivadekar Introduction to GCP. A S Nanivadekar Outline Definition and scope Definition and scope Purpose of clinical research Purpose of clinical.

Building Quality Assurance into Clinical Trials. Objectives for Today: Define Quality in Research Describe How to Initiate Corrective and Preventative.

Ajaz S. Hussain, Ph.D. Deputy Director Office of Pharmaceutical Science, CDER, FDA ACPS Subcommittee on Manufacturing Science: Identification and Prioritization.

Reproductive Health Drugs, Pregnancy Labeling Subcommittee Meeting March 28-29, 2000 Holli A. Hamilton, M.D., M.P.H. Pregnancy Labeling Team Office of.

Drug Submissions: Review Process Agnes V. Klein, MD Biologics and Genetic Therapies Directorate February, 2003 www/hc-sc.gc.ca/hpb-dgps/therapeut.

FDA Science Board Drug Safety Initiative April 15, 2005 Rockville, MD RADM Steven Galson, MD, MPH Acting Director, Center for Drug Evaluation and Research.

Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.

RTI Health Solutions Research Triangle Park North Carolina, US US Manchester, UK UK 44(0) LEADING RESEARCH… MEASURES.

FDA Risk Management Workshop: Concept Paper: Risk Management Programs April 10, 2003 Gary C. Stein, Ph.D. Director of Federal Regulatory Affairs American.

Joint Meeting of Anti-Infective Drugs & Drug Safety and Risk Management Advisory Committees December 14-15, 2006 Ketek  (telithromycin) Regulatory History.

1 Lotronex Postmarketing Experience Ann Corken Mackey, R.Ph., M.P.H. Allen Brinker, M.D., M.S. Zili Li, M.D., M.P.H., formerly of ODS Office of Drug Safety.

CI-1 Zelnorm ® (tegaserod maleate) Gastrointestinal Drugs Advisory Committee Meeting July 14, 2004 Gastrointestinal Drugs Advisory Committee Meeting July.

Integrating Compliance with Business: Developing and Implementing the Tysabri Risk Map Reintroduction of a Breakthrough Medical Product November 09, 2006.

Center for Drug Evaluation and Research (CDER) Tanya Eberle Kamal Diar David Clements.

History of Pediatric Labeling

CDER Drug Safety Oversight Board Douglas C. Throckmorton, M.D. Deputy Director, CDER Food and Drug Administration November 5, 2005.

Acute Myocardial Infarction (Heart Attack) Committee Membership: B. Majcher, APRN, C. Mulhall, APRN, K. McLean, MD, M. Jarotkiewicz MBA, M. Morrow, RN,

Over-the-Counter Drug Products Over-the-Counter (OTC) drug products are those drugs that are available to consumers without a prescription. There.

7asdf Omapatrilat in the Treatment of Hypertension NDA FDA Cardiovascular and Renal Drugs Advisory Committee Meeting July 19, 2002 Anthony Waclawski,

FDA Science Board CDER Drug Safety Update November 6, 2005 Rockville, MD Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research Food.

July 15, Postmarketing Safety Evaluation of Approved Drugs and Risk Management Victor F. C. Raczkowski, MD, MS Director, Office of Drug Safety July.

1 Lotronex: Clinical Trials Thomas Permutt Division of Biometrics II with David Hoberman, Ph.D. Zili Li, M.D.

Research in the Office of Vaccines Research and Review: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation and Research.

RESTICTED DRUGS Risk Evaluation and Mitigation Strategies--REMS

1 Drug Safety Oversight Board: Recent Activities FDA Science Board Advisory Committee Meeting March 31 st, 2006 Douglas C. Throckmorton, MD Deputy Director.

Research in the Office of Cellular, Tissue and Gene Therapies: Vision and Overview Jesse Goodman, M.D., M.P.H. Director, Center for Biologics Evaluation.

1 Estimating CDER Resources Devoted to Safety Theresa M. Mullin, Ph.D. Office of Planning, Office of Commissioner April 15, 2005 Presentation to: FDA Science.

27 June 2000Victor F. C. Raczkowski, M.D.1 Benefit-Risk Reevaluation of Marketed Drugs Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory.

Zelnorm ® (tegaserod) Division of Gastrointestinal and Coagulation Drug Products Division of Drug Risk Evaluation Gary Della’Zanna, D.O., M.Sc., F.A.C.O.S.

1 FDA Guidance for Industry Development and Use of Risk Minimization Action Plans Anne Trontell, M.D., M.P.H. Deputy Director CDER Office of Drug Safety.

Center for Biologics Evaluation and Research, FDA Site Visit Introduction Kathryn M. Carbone, M.D. Associate Director for Research.

Charge to the Committee Mark Goldberger, M.D., M.P.H. Director, Office of Drug Evaluation IV CDER / FDA.

FDA Advisory Committee for Pharmaceutical Science and Clinical Pharmacology July 22-23, 2008 Introduction and Update Helen N. Winkle Director, Office of.

Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

1 FDA’s Communication of Drug Safety Steven Galson, MD, MPH Director, Center for Drug Evaluation and Research December 7-8, 2005 Welcome – Opening Remarks.

Marianne M. Elliott Office of Research Integrity and Ethics Bureau of Medicine and Surgery U. S Navy.

27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.

FDA’s Role in the Risk Management of Opiate Analgesics Steven Galson, M.D., M.P.H. Deputy Center Director, Center for Drug Evaluation and Research Food.

Pharmacy & Therapeutics Committee Presentation Developed for the Academy of Managed Care Pharmacy Updated: February 2016.

Strengthening the Medical Device Clinical Trial Enterprise

Clinical Review Process for New Drug Development and Application

Pharmacy & Therapeutics Committee

Comments to the FDA on Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription Marissa Schlaifer, RPh Director of Pharmacy.

Patient Focused Drug Development An FDA Perspective

FDA’s IDE Decisions and Communications

FDA Perspective on Cardiovascular Device Development

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

FDA-CDRH in the Next Decade A Vision for Change

Pharmacy & Therapeutics Committee

Comments to the FDA on Conditions of Safe Use To Expand Which Drug Products Can Be Considered Nonprescription Marissa Schlaifer, RPh Director of Pharmacy.

Quality Assurance Session 6.

Development Plans: Study Design and Dose Selection

Pharmacy & Therapeutics Committee

Costanza Schivi - 9 April 2019

Pharmacy & Therapeutics Committee

Presentation transcript:

1 Lotronex ® (alosetron HCl) Tablets Introduction Victor F. C. Raczkowski, M.D. Director, Division of Gastrointestinal and Coagulation Drug Products April 23, 2002

2 Center for Drug Evaluation and Research (CDER) A CDER priority: –Assure that safe and effective drugs are available to the American Public Basis of regulatory decisions: –Laws and regulations –Scientific evidence –Judgement

3 Need for Joint Advisory Committee Public debate over Lotronex –Safety of Lotronex –Access to Lotronex New data about Lotronex –Clinical-trial data –Post-marketing data

4 Issues for this Joint Advisory Committee Can conditions be described for which benefits of Lotronex exceed the risks? –Describe patients –Describe physicians Does the GSK risk-management plan adequately ensure appropriate use of Lotronex?

5 Issues (continued) How is the success of the plan best monitored or audited: –At the level of the patient? –At the level of the physician? –At the level of the pharmacist?

6 Issues (continued) Describe criteria for success of the plan: –Process controls –Evaluation of outcomes

7 FDA Presentations Clinical-Trial Experience Post-Marketing Experience Risk-Benefit Issues Risk-Management Program Summary and Conclusions Thomas Permutt, Ph.D. Ann Corken Mackey, M.P.H. Victor F. C. Raczkowski, M.D. Toni Piazza-Hepp, Pharm. D. Victor F. C. Raczkowski, M.D.